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Members of the large ETS family of transcription factors
(TFs) have highly similar DNA-binding domains (DBDs)—
yet they have diverse functions and activities in physiol-
ogy and oncogenesis. Some differences in DNA-binding
preferences within this family have been described, but
they have not been analysed systematically, and their
contributions to targeting remain largely uncharacterized.
We report here the DNA-binding proﬁles for all human and
mouse ETS factors, which we generated using two differ-
ent methods: a high-throughput microwell-based TF DNA-
binding speciﬁcity assay, and protein-binding microarrays
(PBMs). Both approaches reveal that the ETS-binding
proﬁles cluster into four distinct classes, and that all ETS
factors linked to cancer, ERG, ETV1, ETV4 and FLI1, fall
into just one of these classes. We identify amino-acid
residues that are critical for the differences in speciﬁcity
between all the classes, and conﬁrm the speciﬁcities
in vivo using chromatin immunoprecipitation followed
by sequencing (ChIP-seq) for a member of each class.
The results indicate that even relatively small differences
in in vitro binding speciﬁcity of a TF contribute to site
selectivity in vivo.
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Introduction
We currently know very little about the molecular mechan-
isms that control tissue-speciﬁc gene expression, and about
the variations in gene expression that underlie many patho-
logical states, including cancer. This is in part due to the lack
of information about the ‘second genetic code’—the binding
speciﬁcities of transcription factors (TFs). Deciphering this
regulatory code will allow us to explain observations (i.e.
ChIP, expression proﬁling) based on biochemical principles.
The ultimate aim is to read the genetic code of gene expres-
sion, that is, understand the expression of genes based on
DNA sequence.
To begin to address these questions, we have in this work
concentrated on the study of the large ETS family of TFs,
whose members have diverse functions and activities in
physiology and oncogenesis (Bartel et al, 2000; Sharrocks,
2001; Kumar-Sinha et al, 2008). The ﬁrst ETS factor identiﬁed
was ETS1, which was discovered as a homolog of the avian
leukaemia virus E26 oncogene in 1983 (Leprince et al, 1983;
Nunn et al, 1983). Subsequent analyses have identiﬁed a total
of 27 and 26 ETS-family members in human and mouse
genomes, respectively (Bult et al, 2008).
ETS factors have both developmental functions (Schober
et al, 2005), and functions in differentiated tissues and cells
(Bartel et al, 2000). They are critical for vasculogenesis/
angiogenesis, hematopoiesis and neuronal development
(Bartel et al, 2000; Vrieseling and Arber, 2006). Cellular
responses to activated ETS factors include cell proliferation,
differentiation and migration (Sharrocks, 2001; Schober et al,
2005), depending on the type and state of the responding cell.
Many ETS proteins, including ETV4 in mammals and Yan
in Drosophila are transcriptional targets of signalling path-
ways (Schober et al, 2005; Vrieseling and Arber, 2006).
Activity of ETS proteins can also be modulated directly by
phosphorylation; members of the ETS and ELK subgroups of
ETS factors mediate transcriptional responses to Ras/MAPK
signalling pathways in species ranging from Caenorhabditis
elegans to humans (Brunner et al, 1994; O’Neill et al, 1994;
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2147Beitel et al, 1995; Sharrocks, 2001). The mechanism of
activation of the ELK factors in response to activation
of Ras also appears to be conserved between species
(Wasylyk et al, 1997).
Translocations altering the activity of several members of
the ETS family are associated with multiple types of human
cancer. In translocations observed in some cancer types, the
ETS DNA-binding domain (DBD) is lost, and the ETS partner
contributes a regulatory domain to another class of DBD
(e.g. ETV6-RUNX1; Golub et al, 1995; Mavrothalassitis and
Ghysdael, 2000). More commonly, the cancer-associated
translocations result in fusion of a strong transcriptional
activator domain to the ETS DBD (e.g. EWS fused to FLI1
or ERG in Ewing’s sarcoma; Delattre et al, 1992; Sorensen
et al, 1994) and/or overexpression of an ETS-family member
due to introduction of a strong cis-regulatory element up-
stream of it (Tomlins et al, 2005, 2007). In fact, the most
common known cancer-associated translocation is the
TMPRSS2-ERG fusion, which introduces a strong androgen
receptor (AR)-dependent regulatory element upstream of the
ERG gene (Tomlins et al, 2005). Together with other translo-
cations involving ETV1 and ETV4, over 50% of all prostate
cancer cases display hyperactivity of ETS proteins (Kumar-
Sinha et al, 2008).
All ETS factors share a conserved winged helix-turn-helix
DBD of B85 amino acids, and all analysed members of this
family bind to a consensus DNA sequence containing a core
50-GGA(A/T)-30 motif (Karim et al, 1990; Nye et al, 1992).
On the basis of phylogenetic analysis of the DBDs, the ETS
family has been subdivided into 12 different subgroups (Laudet
et al, 1999; Hollenhorst et al, 2007). Thus, although all ETS
DBDs are relatively highly conserved, different ETS proteins
might exhibit a preference for different ﬂanking sequences to
differentially bind to speciﬁc DNA sites, and thus regulate
distinct biological processes. However, there exists no systema-
tic and uniform analysis of ETS-binding speciﬁcities, and
whether differences in binding speciﬁcity (if any) relate to
targeting in vivo. An earlier analysis showed that there were
differences between published motifs for different ETS-family
members, but these differences did not reﬂect amino-acid
features, and might be due to differences in the experimental
methods used in different studies (Kielbasa et al, 2005).
In this work, we describe the ﬁrst comprehensive genome-
wide analysis of binding speciﬁcities of the ETS TF family.
We ﬁnd that the ETS-family DNA-binding speciﬁcities fall into
four distinct classes, and conﬁrm this ﬁnding by identifying
the key DNA-contact amino acids that contribute to class
speciﬁcity. We further perform ChIP-seq analyses for repre-
sentative ETS factors to map the ETS-binding sites in vivo in
Ewing’s sarcoma, leukaemia and prostate cancer cells. These
analyses provide a systematic genome-wide map of ETS DNA-
binding speciﬁcities in vitro and in vivo. Remarkably, the
genome-wide data reveal that even small differences in ETS
DNA-binding preferences can contribute to in vivo targeting
speciﬁcities.
Results
Systematic determination of ETS-binding speciﬁcities
To determine the binding speciﬁcities of the ETS factors, we
ﬁrst cloned all human and mouse ETS DBDs and human ETS
full-length cDNAs (Figure 1; Supplementary Table S1). Two
parallel methods were used to independently determine
relative DNA sequence-speciﬁc binding afﬁnities: high-
throughput microwell-based TF DNA-binding speciﬁcity
assay (Hallikas and Taipale, 2006; Hallikas et al, 2006) and
protein-binding microarrays (PBMs; Berger et al, 2006). As
these two strategies are based on different principles, they act
to complement and cross-validate each other.
In the microwell-based assay, human and mouse ETS
DBDs were expressed as fusion proteins to a Renilla luciferase
enzyme. The TF-Renilla luciferase fusion proteins were in-
cubated with biotinylated double-stranded oligonucleotide
containing a sequence with high afﬁnity to all known ETS
factors in the presence of an excess of mismatched competitor
oligos. The binding data were then analysed to produce a
position weight matrix (PWM) of the TF-binding site.
Independent analysis of the mouse ETS family was carried
out using PBMs, which allow determination of TF-binding
speciﬁcities through sequence-speciﬁc binding of individual
TFs directly to double-stranded DNA microarrays containing
all possible 10-mer binding sites (Berger et al, 2006).
Both methods generated similar binding proﬁles (Figure 1;
Supplementary Table S2), with all of the ETS factors binding
to the previously described core GGA(A/T) motif. Of the 27
factors we studied, 13 had been previously analysed using
different methods to yield a partial binding speciﬁcity. Our
results were similar, but not identical, to these earlier studies,
as described in the following sections.
Analysis of the divergence of ETS TF-binding proﬁles
We next analysed the differences in the obtained proﬁles to
determine which ETS factors have similar binding speciﬁci-
ties. For this purpose, we developed a computational method
that allows determination of similarity between TF motifs
using the minimum Kullback–Leibler divergence between all
translations and reverse complementations of the multino-
mial distributions deﬁned by the motifs. This analysis re-
vealed that all ETS proﬁles were relatively similar to each
other, and clearly divergent from publicly available non-ETS
TF-binding proﬁles (Figure 2). The ETS-binding proﬁles fell
into four distinct classes (Figure 2), containing 15, 8, 3 and 1
member(s), respectively. These classes were robustly identi-
ﬁed using results either only from the microwell-based meth-
od (Figure 2), from only the PBM method (Figure 3A and B)
or from the combination of the two (Supplementary Figure
S1A). The classes were named according to their respective
sizes, with class I being the largest group, containing the
cancer-associated ETS factors ERG, ETV1, ETV4 and FLI1.
Consistent with earlier results (Kielbasa et al, 2005), cluster-
ing analysis of ETS factors available from current databases
and literature did not yield a clear classiﬁcation of sites
(Figure 3C; Supplementary Figure S3). However, the classes
we obtained do show a clear relationship to groupings based
on amino-acid features (see below and Discussion).
The main differences between our motifs are concentrated
on the core þ4 position and 50 ﬂanking base pairs. Although
the consensus sequences of the ETS factors are relatively
similar, many somewhat weaker sites are much more class
speciﬁc or exclude one or more classes of ETS DBDs
(Supplementary Figure S2). Only the difference between
other ETS-family members analysed and the lone class IV
factor SPDEF has been identiﬁed earlier (Oettgen et al, 2000).
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clustering seemed to be largely sufﬁcient to explain the
differences between the ETS-family members. However,
ETV6 and ETV7 appeared to have subtly different binding
speciﬁcity at þ4 compared with the other members of class
II (Figure 1), and in this way resembled more the class III
factors. We therefore propose subclassiﬁcation of class II into
class IIa containing the ELF-family factors, and class IIb
comprising ETV6 and ETV7.
Molecular basis of ETS-class speciﬁcity
To analyse the molecular basis of the differences in ETS-
binding speciﬁcities, we investigated the amino acid-DNA
contacts in published crystal structures of ETS1, GABPA,
ELK1, ELF3, SPI1 and SPDEF–DNA complexes
(Kodandapani et al, 1996; Batchelor et al, 1998; Mo et al,
1998, 2000; Garvie et al, 2001; Verger and Duterque-
Coquillaud, 2002; Pufall et al, 2005; Wang et al, 2005;
Lamber et al, 2008; Agarkar et al, 2010). The invariant GGA
Figure 1 Structural organizations and binding speciﬁcities of mammalian ETS transcription factors. (Left) Schematic representation of the
domain structures of the respective full-length proteins. ETS domain is in blue, pointed domain is in green, Proline-rich domain is in grey, and
the Nuc_orp_HMR_rcpt and A/T hook domains are in dark yellow and black, respectively. HUGO gene names are from ENSEMBL and protein
domains are from Pfam. The second and third columns, respectively, show human and mouse ETS-binding proﬁles determined using
microwell-based transcription factor-DNA-binding assays. The right column shows mouse ETS-binding proﬁles determined using protein-
binding microarrays. The logos are drawn using enoLOGOS (Workman et al, 2005), and the height of a letter at a particular position is directly
proportional to the effect of that nucleotide on the binding afﬁnity. Coordinates for the bases are also indicated above each column (see also
Supplementary Figures S1 and S9; Supplementary Tables S1, S2 and S6; Supplementary data ﬁle S1).
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absolute conservation of two key DNA-contacting arginines
in Helix3 (Figure 4A, black). Most of the differences in DNA-
binding speciﬁcity at particular bases, in turn, correlate with
corresponding changes in residues contacting DNA at or near
these bases (Figure 4B). The preference of the lone class IV
factor, SPDEF for T at þ4 correlates with the presence of
serine and glutamine at DNA-contact residues 9 and 11,
respectively. Recent crystal structure analysis of SPDEF–
DNA complex suggested that combination of these residues
is responsible for the preference of T at þ4 (Wang et al,
2005). We conﬁrmed the importance of these two residues
by mutagenesis followed by microwell-based DNA-binding
speciﬁcity assay (Figure 4C).
Class I factors are characterized by low afﬁnity to C in
the  3 position. This change correlates with a substitution of
a leucine that contacts DNA backbone at  2 and  3 with
a phenylalanine or tyrosine (Figure 4B, red). Mutation of
the leucine residue to either tyrosine or phenylalanine in
the context of the class II factor ELF4-DBD resulted in a
clear shift of speciﬁcity towards class I at  3 position,
conﬁrming the importance of this amino acid for the differ-
ences in speciﬁcity between class I and the other classes
(Figure 4D).
Whereas Class IIa factors did not have major features that
differentiated them from all other classes, class IIb factors
displayed strong preference for A at þ4. This change corre-
lated with a substitution of a key tyrosine by a histidine.
Mutation of this residue in ELF4-DBD increased binding to
sequences containing A at þ4, conﬁrming the importance of
this residue in class IIb speciﬁcity (Figure 4D).
Class III factors were characterized by preference of G and
Ca t 2 and  1, respectively, strong preference for A at þ4,
and relatively strong binding of sites with a C at þ5. Many
amino-acid residues within the DBD are speciﬁc for class III
(Figure 4B). As the tyrosine that affects speciﬁcity at þ4i s
replaced in class III by an asparagine, we ﬁrst investigated the
function of this amino-acid change. Mutating the tyrosine to
Figure 2 ETS-binding speciﬁcity. Clustering analysis of binding proﬁles of human (h) and mouse (m) ETS transcription factors (microwell
method) and publicly available non-ETS-family transcription factor matrices from Jaspar2 (Bryne et al, 2008; http://jaspar.genereg.net). The
four different classes of ETS factors are indicated by colour: class I, red; class II, blue; class III, green; class IV, brown. Coloured dots indicate the
main branches deﬁning the classes. ETS matrices indicated as ‘class’ are the representative matrices for the different ETS classes identiﬁed
using afﬁnity propagation clustering (see Materials and methods for details). Representative logos, drawn using enoLOGOS (Workman et al,
2005), are also shown. Bases displaying the most prominent changes are boxed (see also Supplementary Figures S2 and S6; Supplementary
data ﬁle S1).
ETS-binding speciﬁcities
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towards that of class III both at þ4 and þ5 (Figure 4D).
Preference for G at  2 in class III could, in turn, be due to
substitution of a tyrosine—which contacts the DNA backbone
between bases  1 and  2—with a glycine or an alanine
(Figure 4B). However, mutation of this residue in ELF4-DBD
to either glycine or alanine had no impact on speciﬁcity.
In contrast, mutation of a class III-speciﬁc glutamate that
contacts water molecule between positions  1 and 1
(Kodandapani et al, 1996) to a glutamine residue led to a
clear change of speciﬁcity of ELF4 towards class III at posi-
tions  1 and  2 (Figure 4D).
Taken together, these results indicate that the ETS DNA-
binding speciﬁcities fall into four clearly distinct classes
(Figures 2, 3A and B), and that the molecular mechanisms
of the differences in four kinds of ETS-binding motifs are due
to amino-acid divergences at deﬁned DNA-contacting resi-
dues (marked 5, 9, 11 and 14 in Figure 4A). The observed
changes in binding speciﬁcity are also consistent with crystal
structures for the ETS-family members (see Figure 5;
Kodandapani et al, 1996; Batchelor et al, 1998; Mo et al,
1998; Mo et al, 2000; Garvie et al, 2001; Pufall et al, 2005;
Wang et al, 2005; Lamber et al, 2008; Agarkar et al, 2010).
ChIP-seq of ETS-binding sites in vivo
To further validate the binding proﬁles, and to examine
binding of ETS factors to DNA in vivo, we used ChIP-seq to
determine occupied sites for each class of ETS factors in cell
lines. Antibodies to endogenous proteins were used in all
experiments. Class I and class IV factors ERG and SPDEF
were analysed in the androgen-dependent prostate cancer cell
line VCaP, and the class II and class III factors ELF1 and SPI1
were analysed in leukaemia cell lines Jurkat and HL60,
respectively. In addition, we included in the analysis two
oncogenic ETS-fusion proteins, EWS/ERG and EWS/FLI1,
which were analysed in the Ewing’s sarcoma cell lines
CADO-ES1 and SK-N-MC, respectively. We also performed
ChIP-seq using two additional antibodies in VCaP cells,
Figure 3 Identiﬁcation of four ETS classes is independent of clustering and binding model derivation methods used. (A) Heat-map correlation
analysis of the protein-binding microarray-derived ETS-binding models. The same four ETS classes are detected when protein-binding
microarray results are clustered using the top 100 TF-binding sites for each ETS-family member (analysis as in Berger et al, 2008). In all, 20
known and 2 predicted mouse ETS-family members are included in the analysis. (B) Kullback–Leibler divergence-based clustering analysis of
mouse ETS-binding proﬁles derived from protein-binding microarrays. Note that this analysis also reveals the same four different classes of ETS
factors, which are indicated in the same colours as in Figures 1 and 2. Coloured dots indicate the main branches deﬁning the classes.
(C) Clustering of existing ETS family binding proﬁles from JASPAR2 (JA), TRANSFAC (TR) professional and literature (Nye et al, 1992;
Treisman et al, 1992; Woods et al, 1992; Dalton and Treisman, 1992; Virbasius et al, 1993; Ray-Gallet et al, 1995; Shore and Sharrocks, 1995;
Matys et al, 2006; Choi and Sinha, 2006; Bryne et al, 2008). Note that the four separate ETS classes are not identiﬁed using the earlier data (see
also Supplementary Figures S3 and S6).
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enhancers, and the non-ETS TF, AR, which served as a
positive control. IgG was used as a negative control in all
cell lines (see Materials and methods for details). Analysis of
the results revealed between 2142 (ERG) and 98290 (H3K4
monomethylation) signiﬁcantly enriched regions (Po0.005),
which we refer to as ‘peaks’ hereafter (Supplementary Table
S4; Supplementary data ﬁles S2–S9). Randomly selected
ChIP-seq peaks were conﬁrmed using ChIP-qPCR (see
Materials and methods; Supplementary Table S5 for details).
For the ETS-fusion proteins EWS/FLI1 and EWS/ERG, the
ChIP-seq peaks were located relatively evenly in the genome.
The non-fusion ETS-family factors ERG, SPDEF and SPI1
demonstrated a relatively small enrichment near transcrip-
Figure 4 Molecular basis of ETS-class speciﬁcity. (A) ETS-domain secondary structure indicating key amino acids contacting nucleotide bases
(black lines), DNA-backbone (brown lines) and water (blue line) based on the published crystal structures of ETS-domain DNA complexes
(Kodandapani et al, 1996; Batchelor et al, 1998; Mo et al, 1998, 2000; Garvie et al, 2001; Pufall et al, 2005; Wang et al, 2005; Lamber et al, 2008;
Agarkar et al, 2010). Amino-acid residues contacting DNA are numbered from 1 to 15. Two invariant arginines that bind to the core GGA
sequence are in black typeface. Bases contributing to DNA-binding speciﬁcity are numbered from  3t oþ7. (B) (Left) Sequence logos showing
amino-acid conservation in DNA-contacting regions of the different ETS classes. Amino acids that are speciﬁc for a given class are indicated by
colours, and the two invariant arginines are in black. (Right) Representative PWMs for the ETS classes. Bases that distinguish each class from
the others are boxed, and residues that contact bases, water or DNA backbone are indicated in black, blue or yellow lines, respectively.
(C) Identiﬁcation of amino-acid residues that are required for class IV DNA-binding speciﬁcity. Mutating key DNA-contact residues in ETS class
IV factor SPDEF (top) to the corresponding residues in ETS class IIa (bottom left) results in a change in DNA-binding speciﬁcity of SPDEF
towards class IIa (bottom right; data from microwell assay). (D) Identiﬁcation of amino-acid residues that can confer class I, IIb or III DNA-
binding speciﬁcity to a class IIa ETS factor. Indicated residues in class IIa ETS DNA-binding domain from mouse ELF4 were mutated to the
corresponding residues in the other ETS classes. The resulting DNA-binding proﬁle from microwell assay is shown on the right. Bases
displaying the most prominent changes are boxed. Note that one or two amino-acid mutations can move the speciﬁcity of ELF4 towards the
other ETS classes. Residues whose mutation to the corresponding residues in class III had no effect on speciﬁcity are indicated in yellow.
ETS-binding speciﬁcities
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ference for binding near TSSs (Figure 6A; Supplementary
Table S4). Consistent with earlier results, we also observed an
enrichment of peaks within potential enhancer elements
identiﬁed by proximity to nucleosomes where Histone H3
lysine 4 is monomethylated (Supplementary Table S4;
Heintzman et al, 2007; Hollenhorst et al, 2009).
To determine whether the ChIP-seq peaks were near genes
regulated by the respective ETS factors, we used RNAi to
downregulate FLI1 in SK-N-MC Ewing’s sarcoma cells. Two
different siRNAs were used to rule out off-target effects
(Echeverri et al, 2006), and two biological replicates were
used for each siRNA to decrease noise. The affected genes
included novel and previously known targets of FLI1 (Tirode
et al, 2007; Supplementary Table S3). FLI ChIP-seq peaks
were strongly enriched near transcription start sites of the
FLI1-target genes (Figure 6B). Although the FLI1 peaks in
general were distributed relatively evenly in the genome, the
enrichment of FLI1 peaks near target genes was strongest
very close to the TSS, suggesting that many of the more distal
peaks have little impact on transcription, whereas more
proximal peaks are more likely to affect gene regulation.
Analysis of speciﬁcity of ETS-family members in vivo
Given the relatively similar DNA-binding speciﬁcities of all
the ETS-family members, an important question is whether
the speciﬁcity of binding comes from the observed relatively
small differences in protein–DNA binding afﬁnity, or whether
direct protein–protein interactions, or more complex chroma-
tin-mediated effects dominate.
To address this, we analysed the ChIP-seq peak sequences
to determine the relative enrichment of sequences that bind
with high afﬁnity to the different ETS classes in vitro.
All ChIP-seq peak sequences were strongly enriched in
matches to matrices representing speciﬁc ETS classes, and
in each case, the most enriched class corresponded to the
class of the factor analysed by ChIP-seq (Figure 6C).
To analyse the sequence characteristics of the peaks
further, we selected sequences from the 150 most signiﬁcant
peaks that were narrower than 400bp for each ChIP-seq
experiment. Searching these sequences for overrepresented
motifs using MEME (Bailey and Elkan, 1994) revealed a clear
ETS-family signature in experiments analysing each ETS
class. The bases characteristic for the different ETS classes
were also conﬁrmed by the MEME analysis (Figure 6D).
However, consistent with earlier results for FLI1 (Gangwal
et al, 2008), analysis of EWS/ERG and EWS/FLI1 peak
sequences resulted in identiﬁcation of a motif resembling
GGAA microsatellite repeats (Supplementary Figure S8A).
This result suggests that the EWS-fusion alters the binding
site selectivity of the ETS proteins.
Although high-afﬁnity in vitro sites were strongly enriched
near the summits of the ChIP-seq peaks, only a small fraction
of such sites in the whole genome were occupied in the
cell lines tested. In ERG and SPDEF ChIP-seq peaks from
VCaP, the fraction of high-afﬁnity sites that were occupied
was much higher within 500bp of regions that were positive
for histone H3 lysine 4 monomethylation, a known marker
for nucleosomes that ﬂank enhancer regions (Heintzman
et al, 2007; Supplementary Table S4). These results suggest
that accessibility of DNA is a major determinant of site
occupancy.
Overlap between different classes of ETS factors
We next analysed the overlap between the sites occupied by
the ETS factors (Figure 7A). As expected, analysis of the same
Figure 5 Crystal structures displaying residues that are critical for ETS-class speciﬁcity. (A) Tyrosine 410 (red) in strand-4 of ETS1 (class I)
contacting DNA backbone between positions  3 and  2 (base G at  3 indicated in blue). This residue is responsible for exclusion of C at
position  3. (B) Glutamine 228 in helix-3 of SPI1 (class III) contacting water molecules (red spheres indicated by asterisks) near DNA positions
 1 (blue) and  2 (cyan). This residue is responsible for preference of G at  2, and weaker binding to C at  1. (C) Asparagine 236 in helix-3
of SPI1 (class III) contacting an adenine at þ4 position. This residue is responsible for stronger preference for A at þ4 and higher-afﬁnity
binding to sites containing a C at þ5. Top parts of each panel display sequence logos for the classes and the DNA sequences used in the
crystallization (Kodandapani et al, 1996; Garvie et al, 2001), with the class-speciﬁc amino-acid residues and bases indicated by colouring.
Contacts between amino acids and DNA backbone, water or bases are indicated using brown, red or black lines, respectively. Images were
generated using PolyView-3D (http://polyview.cchmc.org/polyview3d.html).
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different factors in the same (ERG and SPDEF both in VCaP)
or similar (FLI1 and ERG in Ewing’s sarcoma; ELFand SPI1 in
leukaemia) type of cell appeared to increase overlap of the
peaks. Still, the majority of the peaks were speciﬁc in all
experiments, with overlap ranging between 0.9% (EWS/FLI1
and SPDEF) and 25.8% (ERG and SPDEF). Strikingly, overlap
between ERG peaks from VCaP and the control AR peaks was
much higher than for any other pair of factors; 44.4% of all
ERG peaks in VCaP cells overlapped with AR peaks
(Figure 7A). GO enrichment analysis revealed that regions
near common AR and ERG peaks are enriched in genes
involved in nucleosome and chromatin assembly (data
not shown).
We further performed comparisons with earlier reports. In
all, 171 (51.3%) of total 333 ELF1-speciﬁc occupancy regions
discovered by ChIP-chip in Jurkat (Hollenhorst et al, 2007)
overlapped with our ELF1 ChIP-seq peaks. For comparison,
we also analysed overlap of our ELF1 ChIP-seq peaks with
recent ChIP-seq data of the ETS-family members ETS1 and
GABPA in Jurkat cells (Valouev et al, 2008; Hollenhorst et al,
2009) (see Materials and methods; Supplementary Table S4
for details). Earlier studies showed the redundant occupancy
of the ETS-family members at promoter proximal regions
(Hollenhorst et al, 2007, 2009). Indeed, comparisons between
overlap results from top signiﬁcant peaks of ETS1, GABPA
and ELF1 showed higher overlap of peaks in promoter
regions (Supplementary Table S4). Outside promoters, it
appears that there is a higher overlap between class I factor
ETS1 and GABPA peaks compared to overlap of either ETS1
or GABPAwith the class II factor ELF1 peaks (Supplementary
Table S4).
As many ETS-family members are known to form compo-
site sites with other TFs, we also analysed the ERG peaks that
overlapped with AR peaks to see whether the strong overlap
between ERG and AR could be explained by the presence of
such a composite site in the overlapping peaks. MEME
analysis of the overlapping peaks yielded separate ETS
and AR signatures, with no obvious composite site
(Supplementary Figure S8B).
Discussion
ETS-binding speciﬁcity
We report here the binding speciﬁcities of all human and
mouse ETS-family TFs. Earlier phylogenetic analyses based
on the ETS domains using the CLUSTALW algorithm have
classiﬁed these factors into 12 different groups (Laudet
et al, 1999; Hollenhorst et al, 2007). We report here that the
ETS-domain DNA-binding speciﬁcities fall into only four
major distinct classes, which we name classes I to IV based
on the number of members in each class. Class II is further
subdivided into classes IIa and IIb, based on a more subtle
change in binding speciﬁcity within this group. The binding
Figure 6 ChIP-seq analysis of the different ETS classes. (A) Relative enrichment of ChIP-seq peaks with respect to transcription start sites. Note
that ELF1 peaks are strongly enriched in promoters, whereas the other non-fusion ETS-family factors ERG, SPDEF and SPI1 display smaller
promoter enrichment. The ETS factors fused to the EWS protein (EWS/FLI1 and EWS/ERG) display the smallest enrichment at promoters.
(B) Enrichment of FLI1 ChIP-seq peaks near transcription start sites of genes that are downregulated in response to FLI1 siRNAs. (C) Analysis
of speciﬁc enrichment of ETS class PWM matches in ChIP-seq peak sequences. Note that sequences immunoprecipitated using antibodies
against a member of a given ETS DNA-binding class are enriched in matches to the PWM representing the same class. (D) MEME analysis of
enrichment of sequence motifs in ChIP-seq peaks from experiments analysing members of all ETS classes (ERG, ELF1, SPI1 and SPDEF). Note
that peaks in ChIP-seq experiments are enriched in motifs (in vivo, bottom) that are similar to those obtained using microwell assay (in vitro,
top). Note also that the in vivo analysis conﬁrms the differences in speciﬁcity of the ETS classes at the class-speciﬁc positions (boxes; see
Figure 2) identiﬁed in vitro. The differences observed between the in vitro and in vivo proﬁles mainly affect the  1 and þ5 positions of ERG
and ELF1, respectively. These differences could be at least in part due to the presence of a high number of GGAA repeat containing ETS sites in
the human genome, as  1 and þ5 positions in sites derived from such repeats are enriched in A and G, respectively. These GGAA repeat-
derived sequences can be functionally important (Gangwal et al, 2008). Colour code: class I, red; class II, blue; class III, green; class IV, brown
(see also Supplementary Figures S8 and S10; Supplementary Tables S3–S6; Supplementary data ﬁles S2–S8).
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that generated by aligning the ETS-domain peptide sequences
from multiple species using the MUST program (Laudet et al,
1999) but differs from that generated by ClustalW using just
human sequences by Hollenhorst et al (2007) or by us
(Supplementary Figures S4 and S5). A tree that is more
consistent with our binding speciﬁcity data was also obtained
using the Prank algorithm (Supplementary Figure S6), which
uses phylogeny-aware gap placement and scores insertions
and deletions more accurately than other alignment programs
(Lo ¨ytynoja and Goldman, 2005, 2008). Alignment analysis of
the ETS domains by Prank fails only to clearly identify the
class II factors as a single group; instead, the class II members
are placed in several branches. One possible explanation is
that the class II represents the ancestral speciﬁcity from
where the other classes diverged.
Of the four classes of the ETS factors, crystal structures
exist for classes I, IIa, III and IV. Our results are consistent
with these structures, and the changes in binding speciﬁcity
correlate with changes in amino acids contacting DNA at or
near the base pairs affected (Figure 5). Our results also
suggest that further structural studies of ETS factors should
concentrate on class IIb factors, and cocrystals between ETS
factors and other TFs.
Earlier studies have suggested that further speciﬁcity exists
within the class I ETS DBDs; Elk4 has been reported to have
higher speciﬁcity towards sequence ACAGGATGT than Elk1
(reviewed in Verger and Duterque-Coquillaud, 2002). These
earlier results are based on SELEX with only 11 and 20
sequences analysed (Shore and Sharrocks, 1995; Shore
et al, 1996) and are not statistically signiﬁcant (not shown).
We do not observe signiﬁcant differences between Elk1 and
Elk4 DNA-binding speciﬁcity in either of the independently
performed DNA-binding speciﬁcity assays, suggesting that
the differences in binding observed earlier were related to
changes in overall afﬁnity of the ETS factors to DNA as
opposed to effect on speciﬁcity of binding to different se-
quences. This interpretation is also supported by existing
crystal structure data (Mo et al, 1998), which indicates that
Tyr 65 of Elk4 makes base-speciﬁc contacts with both Tand A
at þ4, whereas the corresponding tyrosine in Elk1 does not
contact DNA at all. This should result in lower overall afﬁnity
of Elk1 to DNA.
The broad biological functions of the distinct classes of
ETS factors do not appear to be clearly separate, for example
class I, IIb and III factors are all involved in hematopoiesis,
albeit at different steps (Bartel et al, 2000). Further class-
speciﬁc functions could, however, be revealed by combining
multiple knockouts within the same ETS class. Gain-of-func-
tion evidence does suggest that there is some class speciﬁcity
in biological functions, as only class I ETS DBDs are found in
cancer-associated fusion proteins. Further analysis of the
critical targets of the oncogenic ETS factors is needed to
reveal the basis of this selectivity.
Assay bias revealed by systematic analysis of binding
speciﬁcities
Existing information seems to indicate that different ETS-
family members have divergent binding speciﬁcities, and no
clear subgroups could be identiﬁed based on clustering of the
existing binding proﬁles (Figure 3C). Our results show that
the previously observed differences are largely attributable to
experimental variation and different methods used rather
than actual differences in speciﬁcity. Similarly, individually
analysed homeobox-TF-binding proﬁles were found to be
more divergent compared with those reported in two syste-
matic studies (Berger et al, 2008; Noyes et al, 2008). Given
the diversity of the currently available binding proﬁles, even
for the same factors (see Figure 3C), it is important that
systematic approaches such as those described here are
extended to all TFs.
These results also highlight the improved precision and
accuracy that can be obtained in high-throughput experi-
ments, where all experiments are similarly designed and
carefully controlled. Protein–DNA interaction analyses neces-
sarily measure a relatively large number of individual afﬁ-
nities. This makes the assay type and laboratory variation
inherent in single-protein studies more apparent than com-
parison between high-throughput and single-protein studies
in other ﬁelds (such as protein–protein interactions, where
only one Kd is measured).
The differences between our completely independently
performed microwell and PBM assays were relatively small,
and comparison using either data set alone did not reveal
more classes of factors than comparisons including all data
(see Supplementary Figure S1A). However, principal compo-
nent analysis of the matrices could be used to separate
matrices based on the assay used (see Supplementary
Figure S1B). Thus, there was a minor systematic difference
between microwell and PBM-derived matrices, but its
Figure 7 Analysis of ChIP-seq data. (A) Overlap between ChIP-seq
peaks. All overlaps are signiﬁcantly enriched compared with ran-
dom expectation (Po0.001), with exception of ELF1 versus AR (in
grey, signiﬁcance P¼0.0013). P-values for each overlap are listed in
Supplementary Table S4. Note that the highest observed overlap
(red bold typeface) in all experiments is between AR and ERG.
Other overlaps over 10% are coloured in brown. (B) Model of
aberrant feed-forward regulation of common androgen receptor and
ETS targets in prostate cancer. In normal cells (left), activation of
AR and ETS-family TFs requires separate signals. In prostate cancer
(right), a strong AR-regulated element is fused to ERG, ETV1 or
ETV4 (indicated by ETS), resulting in an aberrant feed-forward loop
(arrows) (see also Supplementary Table S4; Supplementary data
ﬁles S2–S8).
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downstream analyses.
ChIP-seq analyses
The ChIP-seq experiments conﬁrmed that the in vitro speci-
ﬁcity analyses were relevant also for TF-binding in vivo
(Figure 6C and D). We found that high-afﬁnity sites were
strongly enriched near the summits of the ChIP-seq peaks,
and that a substantial fraction of high-afﬁnity sites within
accessible genomic regions were occupied (Supplementary
Table S4). In addition, comparison of ChIP-seq data to
expression proﬁling data revealed that only a small fraction
of FLI1 ChIP-seq peaks are located in close proximity to genes
that are strongly regulated by loss of FLI1. Whereas FLI1
peaks were located randomly with respect to transcription
start sites, enrichment of FLI1 peaks near FLI1-target genes
was clearly higher near the TSS (Figure 6B). It thus appears
that most occupied sites have little if any effect on gene
expression, and that proximity of the occupied site to a TSS is
important in determining whether an ETS binding event
affects transcription. However, it is well established that
long-range enhancers have pivotal functions in mammalian
gene regulation (Heintzman and Ren, 2009), and our results
do not mean that all distal sites are non-functional.
Although overlap was observed between the different ETS
classes, most of the peaks observed were speciﬁc for a given
factor, underscoring the speciﬁcity of the ETS-family mem-
bers. A notable exception was found in the VCaP prostate
cancer cell line. Activity of two classes of TFs, the AR, and the
class I ETS factors ERG, ETV1 and/or ETV4 are implicated in
prostate cancer. We found here that a very large fraction
(44.4%) of ERG occupied sites are close to sites occupied by
AR, and 30.4% of these sites are also bound by SPDEF (not
shown). These results suggest that the translocation/deletion
that places a strong androgen-responsive element from the
TMPRSS2 gene adjacent to the ERG-coding sequences will
result in aberrant feed-forward regulation of target genes
common to both AR and ERG (Figure 7B).
Basis of speciﬁcity of TFs
The human genome contains large number of TFs contribut-
ing to complex gene regulation, accurate developmental
patterning and growth control (Messina et al, 2004). Many
classes of TFs, including members of the ETS and HOX
families have relatively similar binding speciﬁcities (Berger
et al, 2008; Noyes et al, 2008). Despite similar speciﬁcities
and overlapping expression patterns (Galang et al, 2004;
Hollenhorst et al, 2004; Richardson et al,2 0 1 0 ;
Supplementary Figure S7), loss-of-function studies have re-
vealed that ETS-family TFs have very speciﬁc functions
during development (Bartel et al, 2000). An important ques-
tion is how such speciﬁcity is achieved despite relatively
similar DNA-binding speciﬁcity.
We provide here direct evidence that even the relatively
small differences in ETS-domain DNA-binding speciﬁcity
affect in vivo site occupancy. Although the consensus se-
quences of the ETS factors are very similar, many somewhat
weaker sites are much more class speciﬁc or exclude one or
more classes of ETS DBDs (Supplementary Figure S2). Such
selectivity is clearly evident also in our ChIP-seq analyses; we
found clear enrichment of class I ETS-binding sites over
binding sites of the other classes in regions immunoprecipi-
tated by the class I ETS-family members ERG and FLI1.
Similar enrichments were observed for all the other classes
as well (Figure 6C). These results indicate that the ETS-class
speciﬁcities reported here contribute to site selectivity of the
ETS-family TFs in vivo.
Whereas it is possible that more sensitive methods could,
in the future, be used to further subdivide ETS-domain DNA-
binding speciﬁcities, such differences would necessarily be
even smaller than those reported here. Thus, it appears that
DNA-binding speciﬁcity differences alone cannot explain the
full diversity of the ETS family, as there are 27 ETS TFs and
four major classes of DNA-binding speciﬁcity. One common
mechanism explaining how loss of similar proteins can cause
different phenotypes is that their expression patterns are
different. In mouse embryos, the ETS-family members show
distinct but partially overlapping expression patterns
(Supplementary Figure S7), suggesting that at least part of
the functional specialization within the classes can be ex-
plained by the divergent expression patterns (Richardson
et al, 2010). This hypothesis is also supported by knock-in
experiments that show that the class III ETS factor SPIB can
replace another class III factor SPI1 (SFPI1) in mouse myeloid
development (Dahl et al, 2002; DeKoter et al, 2002).
In contrast, the class I ETS factor ETS1 cannot rescue SFPI1 loss.
Another important mechanism to achieve speciﬁcity in-
volves cooperative binding of ETS factors with other TFs. The
protein-binding surfaces of ETS factors are different, and
different ETS factors associate with different other TFs to
bind distinct composite sites (Verger and Duterque-
Coquillaud, 2002). For example, the class I factors ETS1,
ELK1, ELK4 and FLI1 have different binding partners. ELK1
or ELK4 can bind DNA together with SRF (Dalton and
Treisman, 1992; Cooper et al, 2007; Boros et al, 2009), FLI1
associates with SMAD3 (Ravasi et al, 2010) and ETS1 can
bind to composite sites with PAX5 (Garvie et al, 2001) and
RUNX1 (Hollenhorst et al, 2007, 2009). In the cases analysed,
the composite sites are distinct from ETS consensus se-
quences either at the ﬂanking regions, or even at the core
region. ETS1 and PAX5 interact to recognize an element
containing a modiﬁed ETS core sequence GGAG instead of
the consensus GGA(A/T) (Fitzsimmons et al, 1996, 2001;
Garvie et al, 2001).
Formation of the composite sites can affect also in vivo
binding speciﬁcity, and this has been demonstrated in the
case of ETS1/RUNX1 (Hollenhorst et al, 2009). Although such
cooperative interactions could potentially explain the differ-
ences we observe in in vivo binding for the members of the
different ETS classes, we did not ﬁnd obvious motifs corres-
ponding to other TFs in our MEME analysis of the ETS
factors ERG, EWS/ERG, EWS/FLI1, ELF1, SPI1 and SPDEF.
This suggests that these factors partner with multiple TFs in
such a way that any given composite site is present in
relatively small numbers—and thus cannot be detected by
the algorithm used. Improvement of methods to systemati-
cally map such interactions between ETS-family members
and other TFs is needed to fully understand in vivo speciﬁcity
differences within each ETS class.
Taken together, in this work, we systematically analysed
the ETS family of TF DNA-binding speciﬁcities for two species
(human and mouse) with a single high-throughput assay
(microwell based). The DNA-binding speciﬁcities of ETS-
family TFs in the mouse genome were determined by two
ETS-binding speciﬁcities
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of in vitro data are consistent and reveal four clear subclasses
of ETS DNA-binding preferences. We further dissected mole-
cular basis for the speciﬁcity in DNA recognition by systema-
tic site-directed mutagenesis of key amino acids in the ETS
DBDs. Through ChIP-seq mapping of ETS-binding sites in
different cell models, we found that the preferences observed
for ETS DNA-binding in vitro can contribute to site selectivity
in vivo on a genome-wide scale.
Materials and methods
Cell culture
SK-N-MC cells were grown in EMEM, Jurkat, HL60, CADO-ES1 in
RPMI1640, and COS1, 293T and VCaP in DMEM. All media were
supplemented with penicillin/streptomycin and fetal bovine serum
(10%).
Cloning
Sequences coding for the human and mouse ETS domains with
10–25 amino acids of ﬂanking sequence (with exception of ETS
domains in N- or C-terminal regions) were cloned into pMAGIC1
(Li and Elledge, 2005) or directly to pGEN expression vector (Taipale
et al, 2002) from Megaman cDNA library (Stratagene) and from
mouse-pooled cDNAs (mouse 12.5 days embryonic and fetal brain
cDNA library; a kind gift from Professor Tomi Ma ¨kela ¨, University of
Helsinki). The inserts in pMAGIC1 were transferred to pMAGIC-
DEST vector containing C-terminal Renilla luciferase. All the human
ETS full-length cDNAs were cloned into Gateway pDONR221 vector.
For expression analyses, the clones were transferred into modiﬁed
pDEST40 (Invitrogen) vectors containing C-terminal triple V5 or
Renilla luciferase tags.
Validation of high-throughput data
Validation of high-throughput data was performed as follows:
TF-binding assays were performed using two different methods in
two different laboratories. The ChIP analyses were validated using
single ChIP-qPCR with different antibodies for 11–42 randomly
selected peaks (Supplementary Table S5). In expression analysis,
two different siRNAs for each factor were used to rule out off-target
effects (Echeverri et al, 2006), and two biological replicates were
used to decrease noise. Thirty-ﬁve randomly selected up- or
downregulated genes were validated using qPCR (Supplementary
Table S5).
Analysis of TF-binding speciﬁcity
Microwell-based TF DNA-binding assay was performed as described
(Hallikas and Taipale, 2006). The method is based on competition
between binding sites, and measures relative sequence-speciﬁc
DNA-binding afﬁnity of a TF. Brieﬂy, TF-Renilla luciferase fusion
proteins expressed in COS1 or 293T cells were incubated with
competitor oligonucleotides indicated in the presence of a
biotinylated oligonucleotide containing the ETS consensus-binding
sequence (Forward: ACGCTAACCGGATATAACGCTA; Reverse: TAGC
GTTATATCCGGTTAGCGT) (Nye et al, 1992; Woods et al, 1992;
Hallikas et al, 2006). A scrambled oligonucleotide (Forward: ACGCT
AAACAGTGTCAACGCTA; Reverse: TAGCGTTGACACTGTTTAGCGT)
was used to control for non-sequence-speciﬁc DNA-binding afﬁnity.
Bound TF-Renilla luciferase activity was measured using
a luminometer (BMG Fluostar Optima) and normalized to yield
TF-binding positional weight matrix as described in Hallikas and
Taipale (2006). DBDs were used to determine binding proﬁles, as
initial experiments indicated that signiﬁcant differences were not
observed between proﬁles obtained using full-length proteins or
DBDs for GABPa or ETS1 (Supplementary Figure S9A). Biotinylated
oligonucleotides with GGAT core sequence were used as this
allowed efﬁcient assay in all classes of ETS factors. Control
experiments indicated that use of GGAT core instead of GGAA did
not markedly affect results (Supplementary Figure S9B). Microwell-
based assay was performed using 3–6 replicate measurements for
each competing DNA sequence (see Supplementary Table S6) for all
factors. Replicate measurements were compared with each other
using the novel algorithm described below. Results shown represent
averages from all replicates that were within minimum Kullback–
Leibler divergence of 0.5 (see below).
Independent analysis of the mouse ETS family was carried out
using PBMs, which analyse binding of TFs to double-stranded DNA
microarrays synthesized with all possible 10bp DNA sequences
(Berger et al, 2006). The ETS TF proteins were puriﬁed from
Escherichia coli or from in vitro translation reactions. Binding
reactions were performed with 39–100nM (see Supplementary
Table S1) of protein using PBM array design #015681 essentially as
described in Berger et al (2006).
Divergence of motifs
Comparison of binding proﬁles was performed using a novel
algorithm that determines the similarity between TF motifs using
the minimum Kullback–Leibler divergence between all translations
and reverse complementations of the multinomial distributions
deﬁned by the motifs. Conceptually, the TF-motif divergence
measures the information gained about the DNA sequence by
knowledge of having binding sites for both of the two factors. The
TF-motif divergence is deﬁned as the minimum Kullback–Leibler
divergence between all translations and reverse complementations
of the multinomial distributions deﬁned by the two TF motifs. The
longer motif is inserted to a sequence with background distribution
and the shorter motif is slid over the background/longer motif
sequence. The KL divergence is computed between the multinomial
distributions deﬁned by (1) the shorter motif and (2) the part of the
background/longer motif sequence overlapping the shorter motif.
The same is repeated with the background/long motif sequence
reverse complemented and the minimum of the KL divergences is
taken. The TF-motif divergence is symmetric but does not fulﬁll the
triangle inequality and thus is not a metric in the mathematical
sense. The TF motifs are clustered with hierarchical average linkage
clustering (Mahony and Benos, 2007) based on the TF-motif
divergences. The TF-motif divergence bears similarity to earlier
comparison strategies (Roepcke et al, 2005; Mahony and Benos,
2007) in the use of KL divergence but as far as we know, taking the
minimum is a novel feature.
Four matrices representative of the different ETS classes were
selected using afﬁnity propagation clustering (Frey and Dueck,
2007). This method does not derive an average, but identiﬁes the
matrix that is most representative of each group (these were used as
the class matrices in Figure 2). The exemplar preferences were
uniform on all motifs and the common preference was selected to
provide pre-chosen number of clusters.
Chromatin immunoprecipitation and sequencing
ChIP analysis of VCaP, Jurkat, HL60, SK-N-MC and CADO-ES1 was
performed as described earlier (Metivier et al, 2003) with minor
modiﬁcations described in Robertson et al (2007). For details and
antibodies used, please see Supplementary data.
A detailed description of ChIP-seq DNA library preparation and
complexity estimation (Supplementary Table S4), peak calling
(Audic and Claverie, 1997; Li et al, 2008; Nix et al, 2008; Laajala
et al, 2009; Pepke et al, 2009), motif analysis by MEME (Bailey and
Elkan, 1994) (Figure 6D; Supplementary Figures S8 and S11), motif
enrichment in peaks and peak overlap analysis is included in the
Supplementary data. Peak positions (NCBI36 coordinates) are in
Supplementary data ﬁles S2–S9, and sequencing reads are publicly
available at NCBI Sequence Read Archive under accession no.
SRA014231.
siRNA treatment and expression proﬁling
For siRNA knockdown of EWS/FLI1 in SK-N-MC, the individual set
of four siRNAs (Qiagen) against each gene were tested for
knockdown efﬁciency by qRT–PCR, and two most effective single
siRNA were used for further experiments (SI00387716 and
SI00387730, Qiagen). The selected FLI1 siRNAs, or non-targeting
control siRNA (Ctrl-control_1, SI03650325, Qiagen) were trans-
fected into cells using HiPerFect Transfection Reagent (Cat. 301704,
Qiagen). The ﬁnal siRNA concentration was 10nM. After 24h, a
second identical transfection was performed, and cells were
harvested 48h later for RNA isolation.
Before expression proﬁling, the efﬁciency of downregulation of
the target gene and a set of known target genes were validated using
real-time PCR (Supplementary Figure S10 and not shown).
Expression proﬁling was performed using Affymetrix human
genome U133plus2.0 arrays. A detailed description of array data
ETS-binding speciﬁcities
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is provided in the Supplementary data.
Quantitative real-time PCR
For ChIP experiments, enrichments of immunoprecipitated DNA
were analysed by Roche LightCycler and Power SYBR Green Master
Mix (Applied Biosystems). Relative enrichment of target DNA
fragments was determined by calculating the immunoprecipitation
efﬁciency above fragment-speciﬁc background (IgG control) fol-
lowed by normalization to the occupancy level observed in control
regions (see Supplementary Table S6 for primers and control
regions used).
For expression analysis of RNAi knockdown efﬁciency, total RNA
was reverse transcribed to cDNA using the High Capacity cDNA RT
Kit (ABI), using 500ng total RNA in a 20-ml reaction. The reactions
were diluted 10-fold, and gene expression levels were determined
from 1 to 3ml of the reactions using qPCR as described above. Each
gene was analysed at least in triplicate and normalized against
endogenous b-actin control.
Supplementary data
Supplementary data are available at The EMBO Journal Online
(http://www.embojournal.org).
Acknowledgements
We thank Ritva Nurmi and Sini Miettinen for technical assistance,
and EMBL gene core, Uppsala SNP platform and Dr Outi Monni for
massively parallel sequencing. This work was supported by the EU
FP6 STREP project REGULATORY GENOMICS, Sigrid Juse ´lius
Foundation, Finnish Cancer Organizations, Biocentrum Helsinki,
Academy of Finland Center of Excellence in Translational Genome-
Scale Biology, and the NEURO program of the Academy of Finland.
MFB and MLB were supported by grant R01 HG003985 from NIH/
NHGRI to MLB.
Conﬂict of interest
The authors declare that they have no conﬂict of interest.
References
Agarkar VB, Babayeva ND, Wilder PJ, Rizzino A, Tahirov TH (2010)
Crystal structure of mouse Elf3 C-terminal DNA-binding domain
in complex with type II TGF-beta receptor promoter DNA. J Mol
Biol 397: 278–289
Audic S, Claverie JM (1997) The signiﬁcance of digital gene
expression proﬁles. Genome Res 7: 986–995
Bailey TL, Elkan C (1994) Fitting a mixture model by expectation
maximization to discover motifs in biopolymers. Proc Int Conf
Intell Syst Mol Biol 2: 28–36
Bartel FO, Higuchi T, Spyropoulos DD (2000) Mouse models in the
study of the Ets family of transcription factors. Oncogene 19:
6443–6454
Batchelor AH, Piper DE, de la Brousse FC, McKnight SL, Wolberger C
(1998) The structure of GABPalpha/beta: an ETS domain-ankyrin
repeat heterodimer bound to DNA. Science 279: 1037–1041
Beitel GJ, Tuck S, Greenwald I, Horvitz HR (1995) The
Caenorhabditis elegans gene lin-1 encodes an ETS-domain pro-
tein and deﬁnes a branch of the vulval induction pathway. Genes
Dev 9: 3149–3162
Berger MF, Badis G, Gehrke AR, Talukder S, Philippakis AA, Pena-
Castillo L, Alleyne TM, Mnaimneh S, Botvinnik OB, Chan ET,
Khalid F, Zhang W, Newburger D, Jaeger SA, Morris QD, Bulyk
ML, Hughes TR (2008) Variation in homeodomain DNA binding
revealed by high-resolution analysis of sequence preferences.
Cell 133: 1266–1276
Berger MF, Philippakis AA, Qureshi AM, He FS, Estep III PW, Bulyk
ML (2006) Compact, universal DNA microarrays to comprehen-
sively determine transcription-factor binding site speciﬁcities.
Nat Biotechnol 24: 1429–1435
Boros J, Donaldson IJ, O’Donnell A, Odrowaz ZA, Zeef L, Lupien M,
Meyer CA, Liu XS, Brown M, Sharrocks AD (2009) Elucidation of
the ELK1 target gene network reveals a role in the coordinate
regulation of core components of the gene regulation machinery.
Genome Res 19: 1963–1973
Brunner D, Ducker K, Oellers N, Hafen E, Scholz H, Klambt C
(1994) The ETS domain protein pointed-P2 is a target of MAP
kinase in the sevenless signal transduction pathway. Nature 370:
386–389
Bryne JC, Valen E, Tang MH, Marstrand T, Winther O, da Piedade I,
Krogh A, Lenhard B, Sandelin A (2008) JASPAR, the open access
database of transcription factor-binding proﬁles: new content and
tools in the 2008 update. Nucleic Acids Res 36: D102–D106
Bult CJ, Eppig JT, Kadin JA, Richardson JE, Blake JA, Mouse
Genome Database Group (2008) The Mouse Genome Database
(MGD): mouse biology and model systems. Nucleic Acids Res 36:
D724–D728
Choi YS, Sinha S (2006) Determination of the consensus DNA-
binding sequence and a transcriptional activation domain for
ESE-2. Biochem J 398: 497–507
Cooper SJ, Trinklein ND, Nguyen L, Myers RM (2007) Serum
response factor binding sites differ in three human cell types.
Genome Res 17: 136–144
Dahl R, Ramirez-Bergeron DL, Rao S, Simon MC (2002) Spi-B can
functionally replace PU.1 in myeloid but not lymphoid develop-
ment. EMBO J 21: 2220–2230
Dalton S, Treisman R (1992) Characterization of SAP-1, a protein
recruited by serum response factor to the c-fos serum response
element. Cell 68: 597–612
DeKoter RP, Lee HJ, Singh H (2002) PU.1 regulates expression of the
interleukin-7 receptor in lymphoid progenitors. Immunity 16:
297–309
Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, Peter M,
Kovar H, Joubert I, de Jong P, Rouleau G (1992) Gene fusion with
an ETS DNA-binding domain caused by chromosome transloca-
tion in human tumours. Nature 359: 162–165
Echeverri CJ, Beachy PA, Baum B, Boutros M, Buchholz F, Chanda
SK, Downward J, Ellenberg J, Fraser AG, Hacohen N, Hahn WC,
Jackson AL, Kiger A, Linsley PS, Lum L, Ma Y, Mathey-Prevot B,
Root DE, Sabatini DM, Taipale J et al (2006) Minimizing the
risk of reporting false positives in large-scale RNAi screens.
Nat Methods 3: 777–779
Falcon S, Gentleman R (2007) Using GOstats to test gene lists for GO
term association. Bioinformatics 23: 257–258
Fitzsimmons D, Hodsdon W, Wheat W, Maira SM, Wasylyk B,
Hagman J (1996) Pax-5 (BSAP) recruits Ets proto-oncogene
family proteins to form functional ternary complexes on a B-
cell-speciﬁc promoter. Genes Dev 10: 2198–2211
Fitzsimmons D, Lutz R, Wheat W, Chamberlin HM, Hagman J
(2001) Highly conserved amino acids in Pax and Ets proteins
are required for DNA binding and ternary complex assembly.
Nucleic Acids Res 29: 4154–4165
Frey BJ, Dueck D (2007) Clustering by passing messages between
data points. Science 315: 972–976
Galang CK, Muller WJ, Foos G, Oshima RG, Hauser CA (2004)
Changes in the expression of many Ets family transcription
factors and of potential target genes in normal mammary tissue
and tumors. J Biol Chem 279: 11281–11292
Gangwal K, Sankar S, Hollenhorst PC, Kinsey M, Haroldsen SC,
Shah AA, Boucher KM, Watkins WS, Jorde LB, Graves BJ,
Lessnick SL (2008) Microsatellites as EWS/FLI response elements
in Ewing’s sarcoma. Proc Natl Acad Sci USA 105: 10149–10154
Garvie CW, Hagman J, Wolberger C (2001) Structural studies of
Ets-1/Pax5 complex formation on DNA. Mol Cell 8: 1267–1276
Golub TR, Barker GF, Bohlander SK, Hiebert SW, Ward DC, Bray-
Ward P, Morgan E, Raimondi SC, Rowley JD, Gilliland DG (1995)
Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute
lymphoblastic leukemia. Proc Natl Acad Sci USA 92: 4917–4921
Hallikas O, Palin K, Sinjushina N, Rautiainen R, Partanen J,
Ukkonen E, Taipale J (2006) Genome-wide prediction of mam-
malian enhancers based on analysis of transcription-factor bind-
ing afﬁnity. Cell 124: 47–59
Hallikas O, Taipale J (2006) High-throughput assay for determining
speciﬁcity and afﬁnity of protein-DNA binding interactions.
Nat Protoc 1: 215–222
ETS-binding speciﬁcities
G-H Wei et al
The EMBO Journal VOL 29 | NO 13 | 2010 &2010 European Molecular Biology Organization 2158Heintzman ND, Ren B (2009) Finding distal regulatory elements
in the human genome. Curr Opin Genet Dev 19: 541–549
Heintzman ND, Stuart RK, Hon G, Fu Y, Ching CW, Hawkins RD,
Barrera LO, Van Calcar S, Qu C, Ching KA, Wang W, Weng Z,
Green RD, Crawford GE, Ren B (2007) Distinct and predictive
chromatin signatures of transcriptional promoters and enhancers
in the human genome. Nat Genet 39: 311–318
Hollenhorst PC, Chandler KJ, Poulsen RL, Johnson WE, Speck NA,
Graves BJ (2009) DNA speciﬁcity determinants associate with
distinct transcription factor functions. PLoS Genet 5: e1000778
Hollenhorst PC, Jones DA, Graves BJ (2004) Expression proﬁles
frame the promoter speciﬁcity dilemma of the ETS family of
transcription factors. Nucleic Acids Res 32: 5693–5702
Hollenhorst PC, Shah AA, Hopkins C, Graves BJ (2007) Genome-
wide analyses reveal properties of redundant and speciﬁc pro-
moter occupancy within the ETS gene family. Genes Dev 21:
1882–1894
Karim FD, Urness LD, Thummel CS, Klemsz MJ, McKercher SR,
Celada A, Van Beveren C, Maki RA, Gunther CV, Nye JA (1990)
The ETS-domain: a new DNA-binding motif that recognizes
a purine-rich core DNA sequence. Genes Dev 4: 1451–1453
Kielbasa SM, Gonze D, Herzel H (2005) Measuring similarities
between transcription factor binding sites. BMC Bioinformatics
6: 237
Kodandapani R, Pio F, Ni CZ, Piccialli G, Klemsz M, McKercher S,
Maki RA, Ely KR (1996) A new pattern for helix-turn-helix
recognition revealed by the PU.1 ETS-domain-DNA complex.
Nature 380: 456–460
Kumar-Sinha C, Tomlins SA, Chinnaiyan AM (2008) Recurrent gene
fusions in prostate cancer. Nat Rev Cancer 8: 497–511
Laajala TD, Raghav S, Tuomela S, Lahesmaa R, Aittokallio T, Elo LL
(2009) A practical comparison of methods for detecting transcrip-
tion factor binding sites in ChIP-seq experiments. BMC Genomics
10: 618
Lamber EP, Vanhille L, Textor LC, Kachalova GS, Sieweke MH,
Wilmanns M (2008) Regulation of the transcription factor Ets-1
by DNA-mediated homo-dimerization. EMBO J 27: 2006–2017
Laudet V, Hanni C, Stehelin D, Duterque-Coquillaud M (1999)
Molecular phylogeny of the ETS gene family. Oncogene 18:
1351–1359
Leprince D, Gegonne A, Coll J, de Taisne C, Schneeberger A,
Lagrou C, Stehelin D (1983) A putative second cell-derived
oncogene of the avian leukaemia retrovirus E26. Nature 306:
395–397
Li H, Ruan J, Durbin R (2008) Mapping short DNA sequencing reads
and calling variants using mapping quality scores. Genome Res
18: 1851–1858
Li MZ, Elledge SJ (2005) MAGIC, an in vivo genetic method for the
rapid construction of recombinant DNA molecules. Nat Genet 37:
311–319
Lo ¨ytynoja A, Goldman N (2005) An algorithm for progressive
multiple alignment of sequences with insertions. Proc Natl Acad
Sci USA 102: 10557–10562
Lo ¨ytynoja A, Goldman N (2008) Phylogeny-aware gap placement
prevents errors in sequence alignment and evolutionary analysis.
Science 320: 1632–1635
Mahony S, Benos PV (2007) STAMP: a web tool for exploring DNA-
binding motif similarities. Nucleic Acids Res 35: W253–W258
Matys V, Kel-Margoulis OV, Fricke E, Liebich I, Land S, Barre-Dirrie
A, Reuter I, Chekmenev D, Krull M, Hornischer K, Voss N,
Stegmaier P, Lewicki-Potapov B, Saxel H, Kel AE, Wingender E
(2006) TRANSFAC and its module TRANSCompel: transcriptional
gene regulation in eukaryotes. Nucleic Acids Res 34: D108–D110
Mavrothalassitis G, Ghysdael J (2000) Proteins of the ETS family
with transcriptional repressor activity. Oncogene 19: 6524–6532
Messina DN, Glasscock J, Gish W, Lovett M (2004) An ORFeome-
based analysis of human transcription factor genes and the
construction of a microarray to interrogate their expression.
Genome Res 14: 2041–2047
Metivier R, Penot G, Hubner MR, Reid G, Brand H, Kos M, Gannon F
(2003) Estrogen receptor-alpha directs ordered, cyclical, and
combinatorial recruitment of cofactors on a natural target pro-
moter. Cell 115: 751–763
Mo Y, Vaessen B, Johnston K, Marmorstein R (1998) Structures of
SAP-1 bound to DNA targets from the E74 and c-fos promoters:
insights into DNA sequence discrimination by Ets proteins. Mol
Cell 2: 201–212
Mo Y, Vaessen B, Johnston K, Marmorstein R (2000) Structure of the
elk-1-DNA complex reveals how DNA-distal residues affect ETS
domain recognition of DNA. Nat Struct Biol 7: 292–297
Nix DA, Courdy SJ, Boucher KM (2008) Empirical methods for
controlling false positives and estimating conﬁdence in ChIP-Seq
peaks. BMC Bioinformatics 9: 523
Noyes MB, Christensen RG, Wakabayashi A, Stormo GD, Brodsky
MH, Wolfe SA (2008) Analysis of homeodomain speciﬁcities
allows the family-wide prediction of preferred recognition sites.
Cell 133: 1277–1289
Nunn MF, Seeburg PH, Moscovici C, Duesberg PH (1983) Tripartite
structure of the avian erythroblastosis virus E26 transforming
gene. Nature 306: 391–395
Nye JA, Petersen JM, Gunther CV, Jonsen MD, Graves BJ (1992)
Interaction of murine ets-1 with GGA-binding sites establishes the
ETS domain as a new DNA-binding motif. Genes Dev 6: 975–990
Oettgen P, Finger E, Sun Z, Akbarali Y, Thamrongsak U, Boltax J,
Grall F, Dube A, Weiss A, Brown L, Quinn G, Kas K, Endress G,
Kunsch C, Libermann TA (2000) PDEF, a novel prostate epithe-
lium-speciﬁc ets transcription factor, interacts with the androgen
receptor and activates prostate-speciﬁc antigen gene expression.
J Biol Chem 275: 1216–1225
O’Neill EM, Rebay I, Tjian R, Rubin GM (1994) The activities of two
Ets-related transcription factors required for Drosophila eye develop-
ment are modulated by the Ras/MAPK pathway. Cell 78: 137–147
Pepke S, Wold B, Mortazavi A (2009) Computation for ChIP-seq and
RNA-seq studies. Nat Methods 6: S22–S32
Pufall MA, Lee GM, Nelson ML, Kang HS, Velyvis A, Kay LE,
McIntosh LP, Graves BJ (2005) Variable control of Ets-1 DNA
binding by multiple phosphates in an unstructured region.
Science 309: 142–145
Ravasi T, Suzuki H, Cannistraci CV, Katayama S, Bajic VB, Tan K,
Akalin A, Schmeier S, Kanamori-Katayama M, Bertin N, Carninci
P, Daub CO, Forrest AR, Gough J, Grimmond S, Han JH,
Hashimoto T, Hide W, Hofmann O, Kawaji H et al (2010) An
atlas of combinatorial transcriptional regulation in mouse and
man. Cell 140: 744–752
Ray-Gallet D, Mao C, Tavitian A, Moreau-Gachelin F (1995) DNA
binding speciﬁcities of Spi-1/PU.1 and Spi-B transcription factors
and identiﬁcation of a Spi-1/Spi-B binding site in the c-fes/c-fps
promoter. Oncogene 11: 303–313
Richardson L, Venkataraman S, Stevenson P, Yang Y, Burton N, Rao
J, Fisher M, Baldock RA, Davidson DR, Christiansen JH (2010)
EMAGE mouse embryo spatial gene expression database: 2010
update. Nucleic Acids Res 38: D703–D709
Robertson G, Hirst M, Bainbridge M, Bilenky M, Zhao Y, Zeng T,
Euskirchen G, Bernier B, Varhol R, Delaney A, Thiessen N,
Grifﬁth OL, He A, Marra M, Snyder M, Jones S (2007) Genome-
wide proﬁles of STAT1 DNA association using chromatin immu-
noprecipitation and massively parallel sequencing. Nat Methods
4: 651–657
Roepcke S, Grossmann S, Rahmann S, Vingron M (2005) T-Reg
Comparator: an analysis tool for the comparison of position
weight matrices. Nucleic Acids Res 33: W438–W441
Schober M, Rebay I, Perrimon N (2005) Function of the ETS transcrip-
tion factor Yan in border cell migration. Development 132: 3493–3504
Sharrocks AD (2001) The ETS-domain transcription factor family.
Nat Rev Mol Cell Biol 2: 827–837
Shore P, Sharrocks AD (1995) The ETS-domain transcription factors
Elk-1 and SAP-1 exhibit differential DNA binding speciﬁcities.
Nucleic Acids Res 23: 4698–4706
Shore P, Whitmarsh AJ, Bhaskaran R, Davis RJ, Waltho JP,
Sharrocks AD (1996) Determinants of DNA-binding speciﬁcity
of ETS-domain transcription factors. Mol Cell Biol 16: 3338–3349
Smyth GK (2004) Linear models and empirical bayes methods for
assessing differential expression in microarray experiments. Stat
Appl Genet Mol Biol 3: Article3
Sorensen PH, Lessnick SL, Lopez-Terrada D, Liu XF, Triche TJ,
Denny CT (1994) A second Ewing’s sarcoma translocation,
t(21;22), fuses the EWS gene to another ETS-family transcription
factor, ERG. Nat Genet 6: 146–151
Taipale J, Cooper MK, Maiti T, Beachy PA (2002) Patched acts
catalytically to suppress the activity of Smoothened. Nature
418: 892–897
Tirode F, Laud-Duval K, Prieur A, Delorme B, Charbord P, Delattre O
(2007) Mesenchymal stem cell features of Ewing tumors. Cancer
Cell 11: 421–429
ETS-binding speciﬁcities
G-H Wei et al
&2010 European Molecular Biology Organization The EMBO Journal VOL 29 | NO 13 | 2010 2159Tomlins SA, Laxman B, Dhanasekaran SM, Helgeson BE, Cao X,
Morris DS, Menon A, Jing X, Cao Q, Han B, Yu J, Wang L, Montie
JE, Rubin MA, Pienta KJ, Roulston D, Shah RB, Varambally S,
Mehra R, Chinnaiyan AM (2007) Distinct classes of chromosomal
rearrangements create oncogenic ETS gene fusions in prostate
cancer. Nature 448: 595–599
Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun
XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE,
Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM (2005) Recurrent
fusion of TMPRSS2 and ETS transcription factor genes in prostate
cancer. Science 310: 644–648
Treisman R, Marais R, Wynne J (1992) Spatial ﬂexibility in ternary
complexes between SRF and its accessory proteins. EMBO J 11:
4631–4640
Valouev A, Johnson DS, Sundquist A, Medina C, Anton E,
Batzoglou S, Myers RM, Sidow A (2008) Genome-wide analysis
of transcription factor binding sites based on ChIP-Seq data. Nat
Methods 5: 829–834
Verger A, Duterque-Coquillaud M (2002) When Ets transcription
factors meet their partners. Bioessays 24: 362–370
Virbasius JV, Virbasius CA, Scarpulla RC (1993) Identity of GABP
with NRF-2, a multisubunit avtivator of cytochrome oxidase
expression, reveals a cellular role for an ETS domain activator
of viral promoters. Genes Dev 7: 380–392
Vrieseling E, Arber S (2006) Target-induced transcriptional control
of dendritic patterning and connectivity in motor neurons by the
ETS gene Pea3. Cell 127: 1439–1452
Wang Y, Feng L, Said M, Balderman S, Fayazi Z, Liu Y, Ghosh D,
Gulick AM (2005) Analysis of the 2.0 A crystal structure of the
protein-DNA complex of the human PDEF Ets domain bound to
the prostate speciﬁc antigen regulatory site. Biochemistry 44:
7095–7106
Wasylyk C, Bradford AP, Gutierrez-Hartmann A, Wasylyk B (1997)
Conserved mechanisms of Ras regulation of evolutionary
related transcription factors, Ets1 and Pointed P2. Oncogene 14:
899–913
Woods DB, Ghysdael J, Owen MJ (1992) Identiﬁcation of nucleotide
preferences in DNA sequences recognised speciﬁcally by c-Ets-1
protein. Nucleic Acids Res 20: 699–704
Workman CT, Yin Y, Corcoran DL, Ideker T, Stormo GD,
Benos PV (2005) enoLOGOS: a versatile web tool for
energy normalized sequence logos. Nucleic Acids Res 33:
W389–W392
Wu Z, Irizarry RA, Gentleman R, Martinez-Murillo F, Spencer F
(2004) A model-based background adjustment for oligonucleo-
tide expression arrays. J Am Stat Assoc 99: 909–917
The EMBO Journal is published by Nature
Publishing Group on behalf of European
Molecular Biology Organization. This work is licensed
under a Creative Commons Attribution-Noncommercial-
ShareAlike3.0UnportedLicense.[http://creativecommons.
org/licenses/by-nc-sa/3.0/]
ETS-binding speciﬁcities
G-H Wei et al
The EMBO Journal VOL 29 | NO 13 | 2010 &2010 European Molecular Biology Organization 2160